Townsquare Capital LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Townsquare Capital LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.5% during the third quarter, Holdings Channel reports. The institutional investor owned 6,831 shares of the biopharmaceutical company’s stock after purchasing an additional 1,430 shares during the period. Townsquare Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $7,180,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of REGN. Quent Capital LLC lifted its stake in shares of Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares in the last quarter. Tidal Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after buying an additional 711 shares in the last quarter. Atria Investments Inc lifted its stake in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after purchasing an additional 941 shares in the last quarter. First City Capital Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $215,000. Finally, Cetera Investment Advisers lifted its stake in Regeneron Pharmaceuticals by 156.8% in the 1st quarter. Cetera Investment Advisers now owns 9,753 shares of the biopharmaceutical company’s stock worth $9,387,000 after purchasing an additional 5,955 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $754.87 on Thursday. The company has a market capitalization of $82.95 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.89 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The firm’s 50-day moving average is $921.45 and its 200 day moving average is $1,022.55. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Wall Street Analyst Weigh In

REGN has been the topic of several research analyst reports. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Evercore ISI decreased their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.